Skip to Content

Lymphocyte immune globulin, anti-thy (equine) Disease Interactions

There are 2 disease interactions with lymphocyte immune globulin, anti-thy (equine):

Moderate

Lymphocyte immune globulin, anti-thy (equine) (applies to lymphocyte immune globulin, anti-thy (equine)) immunocompromised

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency, Vaccination

Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine). Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient. There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists. If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.

Moderate

Lymphocyte immune globulin, anti-thy (equine) (applies to lymphocyte immune globulin, anti-thy (equine)) renal/liver

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine). It is recommended to evaluate these tests closely in these patients.

Lymphocyte immune globulin, anti-thy (equine) drug interactions

There are 109 drug interactions with lymphocyte immune globulin, anti-thy (equine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.